{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:02:31Z","timestamp":1784599351256,"version":"3.55.0"},"reference-count":33,"publisher":"ARAN Ediciones","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.hipert.2023.08.001","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T05:19:18Z","timestamp":1700630358000},"page":"215-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Primary aldosteronism: Practical recommendations for treatment and follow-up"],"prefix":"10.20960","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0519-0072","authenticated-orcid":false,"given":"M.","family":"Araujo-Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pascual-Corrales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mart\u00edn Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Parra Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8588","reference":[{"key":"10.1016\/j.hipert.2023.08.001_bib0170","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S2213-8587(21)00210-2","article-title":"Diagnosis and treatment of primary aldosteronism","volume":"9","author":"Reincke","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.hipert.2023.08.001_bib0175","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/HJH.0000000000002510","article-title":"Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension","volume":"38","author":"Mulatero","year":"2020","journal-title":"J Hypertens"},{"key":"10.1016\/j.hipert.2023.08.001_bib0180","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hipert.2023.08.001_bib0185","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1365-2265.2007.02898.x","article-title":"Diagnosis and treatment of low-renin hypertension","volume":"67","author":"Mulatero","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.hipert.2023.08.001_bib0190","first-page":"22","article-title":"Cardiovascular events and all-cause mortality in surgically or medically treated primary aldosteronism: a meta-analysis","author":"Jing","year":"2021","journal-title":"JRAAS"},{"key":"10.1016\/j.hipert.2023.08.001_bib0195","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1530\/EJE-22-0375","article-title":"Cardiovascular outcomes and all-cause mortality in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a meta-analysis","volume":"187","author":"Chen","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.hipert.2023.08.001_bib0200","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1530\/EJE-19-0215","article-title":"Therapy of endocrine disease: medical treatment of primary aldosteronism","volume":"181","author":"Lechner","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.hipert.2023.08.001_bib0205","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s12020-022-03029-4","article-title":"Evolution of the cardiometabolic profile of primary hyperaldosteronism patients treated with adrenalectomy and with mineralocorticoid receptor antagonists: results from the SPAIN-ALDO Registry","volume":"76","author":"Araujo-Castro","year":"2022","journal-title":"Endocrine"},{"key":"10.1016\/j.hipert.2023.08.001_bib0210","doi-asserted-by":"crossref","DOI":"10.1530\/EC-23-0043","article-title":"Autonomous cortisol secretion in patients with primary aldosteronism: prevalence and implications regarding cardiometabolic profile and surgical outcomes","author":"Araujo-Castro","year":"2023","journal-title":"Endocr Connect"},{"key":"10.1016\/j.hipert.2023.08.001_bib0215","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s12020-022-03029-4","article-title":"Evolution of the cardiometabolic profile of primary hyperaldosteronism patients treated with adrenalectomy and with mineralocorticoid receptor antagonists: results from the SPAIN-ALDO Registry","volume":"76","author":"Araujo-Castro","year":"2022","journal-title":"Endocrine"},{"key":"10.1016\/j.hipert.2023.08.001_bib0220","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","article-title":"Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort","volume":"5","author":"Williams","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.hipert.2023.08.001_bib0225","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/jch.12916","article-title":"Proportion of patients with hypertension resolution following adrenalectomy for primary aldosteronism: a systematic review and meta-analysis","volume":"18","author":"Benham","year":"2016","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.hipert.2023.08.001_bib0230","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1097\/HJH.0000000000003284","article-title":"Predictive model of hypertension resolution after adrenalectomy in primary aldosteronism: the SPAIN-ALDO score","volume":"40","author":"Araujo-Castro","year":"2022","journal-title":"J Hypertens"},{"key":"10.1016\/j.hipert.2023.08.001_bib0235","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgad400","article-title":"Impact of obesity on clinical characteristics of Primary Aldosteronism patients at diagnosis and post-surgical response","author":"Ruiz-S\u00e1nchez","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.hipert.2023.08.001_bib0240","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/cen.14630","article-title":"Preoperative mineralocorticoid receptor antagonist reduces postoperative hyperkalaemia in patients with Conn syndrome","volume":"96","author":"Zhang","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.hipert.2023.08.001_bib0245","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1507\/endocrj.EJ21-0508","article-title":"Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021","volume":"69","author":"Naruse","year":"2022","journal-title":"Endocr J"},{"key":"10.1016\/j.hipert.2023.08.001_bib0250","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.hipert.2023.08.001_bib0255","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jaad.2018.10.023","article-title":"Lack of evidence for feminization of males exposed to spironolactone in utero: a systematic review","volume":"80","author":"Liszewski","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.hipert.2023.08.001_bib0260","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pharmthera.2015.07.006","article-title":"Pharmacological treatment of aldosterone excess","volume":"154","author":"Deinum","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.hipert.2023.08.001_bib0265","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ando.2016.04.009","article-title":"Primary aldosteronism and pregnancy","volume":"77","author":"Landau","year":"2016","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.hipert.2023.08.001_bib0270","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.hipert.2023.08.001_bib0275","first-page":"29","article-title":"Personalized treatment of patients with primary aldosteronism","author":"Obeid","year":"2023","journal-title":"Endocr Pract"},{"key":"10.1016\/j.hipert.2023.08.001_bib0280","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1161\/HYPERTENSIONAHA.120.16440","article-title":"Altered taste perception for sodium chloride in patients with primary aldosteronism: a prospective cohort study","volume":"77","author":"Adolf","year":"2021","journal-title":"Hypertens (Dallas, Tex 1979)"},{"key":"10.1016\/j.hipert.2023.08.001_bib0285","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","article-title":"Long-term renal outcomes in patients with primary aldosteronism","volume":"295","author":"Sechi","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.hipert.2023.08.001_bib0290","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1210\/jc.2008-1851","article-title":"Risk factors associated with a low glomerular filtration rate in primary aldosteronism","volume":"94","author":"Reincke","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.hipert.2023.08.001_bib0295","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.hipert.2023.08.001_bib0300","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41440-022-01045-5","article-title":"Importance of dietary salt restriction for patients with primary aldosteronism during treatment with mineralocorticoid receptor antagonists: the potential importance of post-treatment plasma renin levels","volume":"46","author":"Yoshida","year":"2023","journal-title":"Hypertens Res"},{"key":"10.1016\/j.hipert.2023.08.001_bib0305","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41440-022-00960-x","article-title":"Association of cardiovascular disease risk and changes in renin levels by mineralocorticoid receptor antagonists in patients with primary aldosteronism","volume":"45","author":"Nomura","year":"2022","journal-title":"Hypertens Res"},{"key":"10.1016\/j.hipert.2023.08.001_bib0310","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1210\/jc.2011-0138","article-title":"Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and\/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically","volume":"96","author":"Ahmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.hipert.2023.08.001_bib0315","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/jc.2017-01442","article-title":"Quality of life in primary aldosteronism: a comparative effectiveness study of adrenalectomy and medical treatment","volume":"103","author":"Velema","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.hipert.2023.08.001_bib0320","doi-asserted-by":"crossref","DOI":"10.1016\/0002-9149(87)91030-7","article-title":"Efficacy and tolerance of spironolactone in essential hypertension","author":"Jeunemaitre","year":"1987","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hipert.2023.08.001_bib0325","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.hipert.2023.08.001_bib0330","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1210\/jc.2008-2245","article-title":"Intrarenal hemodynamics in primary aldosteronism before and after treatment","volume":"94","author":"Sechi","year":"2009","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183723000673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183723000673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:15:30Z","timestamp":1784596530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1889183723000673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1889183723000673"],"URL":"https:\/\/doi.org\/10.1016\/j.hipert.2023.08.001","relation":{},"ISSN":["1889-1837"],"issn-type":[{"value":"1889-1837","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary aldosteronism: Practical recommendations for treatment and follow-up","name":"articletitle","label":"Article Title"},{"value":"Hipertensi\u00f3n y Riesgo Vascular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hipert.2023.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of SEH-LELHA.","name":"copyright","label":"Copyright"}]}}